Publication date: May 30, 2025
Objectives: This study aims to assess the adjuvant effects of lentinan and its combination with Mn(J), a manganese-based colloidal adjuvant, on the BG (fusion protein BfrB-GrpE of Mycobacterium tuberculosis) subunit vaccine. Methods: A rabbit skin infection model was established to evaluate the immune protection conferred by the BG-lentinan vaccine, the BG-lentinan/Mn(J) vaccine, and the Bacillus Calmette-GucE9rin (BCG) vaccine against tuberculosis. Rabbits were vaccinated at weeks 0, 2, and 4. Six weeks post-vaccination, antigen-specific IgG levels were measured, followed by a BCG skin challenge. Results: Both the BG-lentinan and BG-lentinan/Mn(J) vaccines significantly increased antigen-specific IgG levels against BfrB and GrpE in rabbits (p < 0. 05). Furthermore, these vaccines accelerated the pathological process following BCG infection. The bacterial load in nodules was notably reduced, with the BG-lentinan vaccine group exhibiting the lowest levels (p < 0. 01). Conclusions: Lentinan and its combined adjuvant, lentinan/Mn(J), significantly enhance the immune response elicited by the BG tuberculosis subunit vaccine, providing effective protection.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Manganese | adjuvant |
| Mycobacterium | combined adjuvant |
| Rabbit | lentinan |
| Vaccines | subunit vaccine |
| Weeks | tuberculosis |